PSNL vs. VRDN, AVAH, TDOC, AHCO, OMDA, GRAL, PNTG, FTRE, FLGT, and CDNA
Should you be buying Personalis stock or one of its competitors? The main competitors of Personalis include Viridian Therapeutics (VRDN), Aveanna Healthcare (AVAH), Teladoc Health (TDOC), AdaptHealth (AHCO), Omada Health (OMDA), GRAIL (GRAL), The Pennant Group (PNTG), Fortrea (FTRE), Fulgent Genetics (FLGT), and CareDx (CDNA). These companies are all part of the "healthcare" industry.
Personalis vs. Its Competitors
Viridian Therapeutics (NASDAQ:VRDN) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.
Viridian Therapeutics currently has a consensus target price of $37.78, indicating a potential upside of 102.45%. Personalis has a consensus target price of $7.42, indicating a potential upside of 51.98%. Given Viridian Therapeutics' higher probable upside, research analysts plainly believe Viridian Therapeutics is more favorable than Personalis.
In the previous week, Viridian Therapeutics and Viridian Therapeutics both had 6 articles in the media. Viridian Therapeutics' average media sentiment score of 1.13 beat Personalis' score of 1.00 indicating that Viridian Therapeutics is being referred to more favorably in the media.
61.9% of Personalis shares are owned by institutional investors. 1.6% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Personalis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Personalis has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.
Personalis has a net margin of -113.70% compared to Viridian Therapeutics' net margin of -112,806.88%. Personalis' return on equity of -47.57% beat Viridian Therapeutics' return on equity.
Viridian Therapeutics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Personalis has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500.
Summary
Personalis beats Viridian Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Personalis News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Personalis Competitors List
Related Companies and Tools
This page (NASDAQ:PSNL) was last updated on 8/26/2025 by MarketBeat.com Staff
MarketBeat All Access